Plexpress Expands Range of Pre-Validated Probes for ADME-Tox Studies
Published: Aug 28, 2012
Jari Rautio, Ph.D., CEO of Plexpress, commented: “TRAC is ideal for ADME-Tox studies as it allows the rapid analysis of an investigational drug in many thousands of samples, without sacrificing the number of genes being analyzed. New compounds likely to be toxic or ineffective can therefore be identified early in the process, before costly clinical trials have taken place.” The use of gene expression to analyze ADME-Tox profiles is widespread in drug discovery, a trend that is likely to continue given a recent draft from report from the FDA suggesting that drug discovery researchers use CYP mRNA induction, rather than CYP activity, to assess drug metabolism and activity (1). Dr Rautio continued: “The TRAC approach has already proved very popular with Biotech, Pharma and Contract Research Organizations, as it offers significant accuracy, speed and cost benefits over more traditional targeted approaches such as qPCR. To-date TRAC been used by over 100 studies to investigate gene expression in a range of experimental systems.”
TRAC uses 96 well plates and avoids the need for RNA extraction, cDNA conversion and amplification, reducing experimental bias. It can also multiplex up to 30 genes per sample, providing expression profiles for all key genes in a single, fast experiment, while minimizing technical variation. The Plexpress Human ADME-Tox panels can feature up to 6 reference genes and numerous targets including 14 CYP450 genes, glucuronosyl transferases, glutathione transferases and ABC transporters. The Plexpress rat ADME-Tox library has over 14 reference genes and more than 120 targets to choose from including hepatotoxicity, necrosis, cholestasis and steatosis markers as well as those associated with drug metabolism and transport pathways.
Depending on the needs of each project, Plexpress can process user’s samples via its ISO9001 certified FAST TRAC gene expression service or assist with setting up TRAC in a user’s own laboratory. TRAC is compatible with most third party magnetic bead processors and capillary electrophoresis devices. Plexpress also offers a ‘one-stop-shop’ for studies requiring fully integrated gene discovery, validation and in-depth analysis. The OneTRAC™ service, offered in collaboration with the Phalanx Biotech Group, combines the coverage breadth of Phalanx Biotech’s OneArray® microarrays with the high-throughput, multiplex capabilities of targeted TRAC analysis, allowing researchers to identify, select and validate a robust set of highly-relevant gene expression signatures. As well as its application in biomarker development, the OneTRAC™ service is fully capable of addressing the diverse needs of academic research projects and drug discovery programs alike.
For more information on the benefits offered by TRAC gene expression analysis, please visit the Plexpress website at www.plexpress.com.
1. FDA Guidance for Industry Report (Feb 2012): Drug Interaction Studies Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations
Plexpress was established as a spinoff from the Finnish Technology Research Center VTT in 2007. Including R&D at VTT, the company’s TRAC technology has been developed continuously for nearly 10 years and it has been documented in over 15 publications. The technology was originally developed for demanding bioprocess applications, which required a very robust solution for gene expression analysis. Since starting operations in 2008, the company has carried out over 50 projects using the TRAC technology in the fields of pharmaceutical development and academic research.
For further information see: www.plexpress.com